Richard Gliklich, a Harvard professor, runs a profitable, closely-held business called Outcome that develops such prospective databases for big drug companies and organizations like the American Heart Association.
The companies he controls--Hollinger Inc. and closely held Ravelston -- have just an 18% economic interest in Hollinger International through Class B shares that have ten times the voting rights of common stock.